Two effective treatments for Chronic Fatigue Syndrome / Myalgic Encephalomyelitis also cost-effective

Two effective treatments for CFS/ME also cost-effective

(Medical Xpress) -- Two treatments found previously to be the most effective for patients with Chronic Fatigue Syndrome or Myalgic Encephalomyelitis (CFS/ME) have now been found to be the most cost-effective treatments according to new research led by King's College London's Institute of Psychiatry.

The latest results from the PACE trial show that both (CBT) and graded (GET), as to specialist medical care, offer good value for money for when the cost of treatment is weighed up against improvement in quality of life. 

CBT and GET were found to be even more cost-effective when the savings to wider society – through a reduced need for additional care by family members – were taken into account. Adaptive pacing therapy (APT) was not cost-effective. 

The research was led by King’s College London, the University of Oxford and Queen Mary, University of London, and was funded by the Medical Research Council (MRC), National Institute for Health Research (NIHR) and UK government departments.

The researchers drew their conclusions in line with healthcare cost criteria used by NICE (National Institute for Health and Clinical Excellence), which considers treatments costing less than £20,000 to £30,000 per year lived in good health (known as a quality-adjusted life years, or QALYs) to represent value for

Professor Paul McCrone, Director of the Centre for the Economics of Mental and Physical Health at King’s College London’s Institute of Psychiatry and lead author of the paper, said: 'It’s very encouraging that two treatments found to help a significant number of CFS/ME patients are also cost-effective based on existing NICE criteria. There is now a strong case for the NHS to invest in providing these therapies. Our research suggests this investment would be justified in terms of improving quality of life for patients and could actually save costs to society if the impact on family members is taken into account.'

Professor Michael Sharpe from Oxford University and a co-author of the paper said: 'In the PACE trial we found that the rehabilitative treatments CBT and GET improve the fatigue and disability of people with CFS/ME. This new analysis of the trial data finds that these treatments are also cost-effective in improving patients’ quality of life. They are potentially cost-saving to society if the time of family and carers is also considered. This new evidence should encourage health service commissioners to provide these treatments to all those patients who need them.'

Professor David Lomas, Chair of the MRC Population and Systems Medicine Board, which co-funded the PACE trial, said: 'CFS/ME has a profound effect on patients and can severely impact their quality of life. These promising findings demonstrate how MRC funding can help to identify treatments that are not only effective, but are financially viable for the health service. There is still a pressing need to understand more about the underlying causes of CFS/ME and we recently announced a further £1.6m of funding for this purpose in the hope it will lead to new diagnostic tools and treatments.'

CFS/ME is a long-term, complex and debilitating condition that affects around 250,000 people in the UK, including children. Symptoms include profound physical and mental fatigue, muscle and joint pain, disturbed sleep patterns and concentration and memory problems. The combination and severity of symptoms varies from patient to patient, making it a difficult condition to diagnose and treat.

In 2011, the first findings from the PACE trial showed that CBT and GET benefit around 60 per cent of patients with CFS/ME, for whom fatigue was the main symptom. The latest study, published in the journal PLOS ONE, compared the cost-effectiveness of each treatment after one year against the criteria used by the NHS watchdog NICE. The researchers looked at the total cost of each course of treatment to the NHS and to wider society through patients requiring time off work and informal care from friends and relatives. 

Specialist was the cheapest option in terms of absolute cost to provide, but when the benefit of treatment on was taken into account, became the most cost-effective option (likelihood of 62.7 per cent). There was a 26.8 per cent likelihood that GET was the most cost effective, while the likelihood for APT and standard care alone were 2.6 and 7.9 per cent, respectively.

More information: McCrone, P. et al. ‘Adaptive pacing, cognitive behaviour therapy, graded exercise, and specialist medical care for chronic fatigue syndrome: A cost-effectiveness analysis’ PLoS ONE  doi:10.1371/journal.pone.0040808

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Obama addresses West Africans on facts about Ebola

6 hours ago

President Barack Obama urged West Africans on Tuesday to wear gloves and masks when caring for Ebola patients or burying anyone who died of the disease. He also discouraged the traditional burial practice ...

Gluten-free diet benefits asymptomatic EmA+ adults

7 hours ago

(HealthDay)—Asymptomatic individuals with endomysial antibodies (EmA) benefit from a gluten-free diet (GFD), according to a study published in the September issue of Gastroenterology.

Another US health worker infected with Ebola

7 hours ago

A third American health worker has tested positive for the Ebola virus while working with patients in West Africa, the Christian missionary group SIM said Tuesday.

UN implores all countries to help on Ebola

9 hours ago

The international group Doctor Without Borders warned Tuesday that the world is 'losing the battle' against Ebola, while U.N. officials implored all countries to quickly step up their response by contributing health experts ...

Travel restrictions could worsen Ebola crisis: experts

13 hours ago

Travel restrictions could worsen West Africa's Ebola epidemic, limiting medical and food supplies and keeping out much-needed doctors, virologists said Tuesday as the disease continued its deadly spread.

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

Tom_Hennessy
not rated yet Aug 02, 2012
Tocopherol phosphate has been shown to have very good effects in those with debilitating fatigue associated with paroxysmal nocturnal hemoglobinuria (PNH).
"The action of alpha-tocopherol phosphate (aTPO4), an
anticoagulant, on PNH"
FirstSong
not rated yet Aug 02, 2012
The key facts in the paper not mentioned above:

Lost employment (number of missed days of work) increased by around 75% from pre-randomisation to the last follow-up, regardless of treatment group.

Additionaly to quote the authors:
"There was no clear difference between treatments in terms of lost employment."

The savings were purely based on lower health care service utilisation and clearly we need better treatments if patients are to recover and go back to work.
DarkHorse66
5 / 5 (1) Aug 03, 2012
Ha Ha Ha HA!
From someone who has six years worth of hard, first hand experience of CFS.(I'm in a long & slow recovery phase.At my worst, simply trying to get up to go to the toilet felt like scaling MtEverest in terms of effort.Even heating up a meal in the microwave felt overwhelming most days.Then I would open up a can & eat it cold(slowly, even eating was tiring). CBT(Smirk).Until the bone-sagging tiredness(this includes brain-tiredness, often too tired to think/brainfog, etc)wears you down again.Sure, it helps to stop you from becoming 2 weak,but the high level of emphasis on exercise is laughable.If you are sick enough, just trying to do basic household chores can exhaust you so much that you spend the next couple of days on your back just trying to recover.I'm back at uni,doing part-time.Even that is still exhausting at times.Physically 2.Until VERY recently, they were still trying to classify CFS as a psychiatric condition.So typical of the English to now turn &declareTHIS.DH66